Page 64 - Haematologica July

S. Tewari et al.
Haematologica. 2010;95(8):1287-1292.
18. Dawson J, Walters M, Delles C, Mischak H, Mullen W. Urinary proteomics to support diagnosis of stroke. PLoS One. 2012;7
(5):e35879.
19. Day TG, Thein SL, Drasar E, et al. Changing
pattern of hospital admissions of children with sickle cell disease over the last 50 years. J Pediatr Haematol Oncol. 2011;33(7):491- 495.
20. Casella JF, King AA, Barton B, et al. Design of the silent cerebral infarct transfusion (SIT) trial. Pediatr Hematol Oncol. 2010;27(2):69- 89.
21. Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014;9(4): e95192.
22. Cheverud JM, Vaughn TT, Pletscher LS, et al. Genetic architecture of adiposity in the cross of LG/J and SM/J inbred mice. Mamm Genome. 2001;12(1):3-12.
23. Rodgers GP, Walker EC, Podgor MJ. Is "rela- tive" hypertension a risk factor for vaso- occlusive complications in sickle cell dis- ease? Am J Med Sci. 1993;305(3):150-156.
24. Gordeuk VR, Sachdev V, Taylor JG, Gladwin MT, Kato G, Castro OL. Relative systemic hypertension in patients with sickle cell dis- ease is associated with risk of pulmonary hypertension and renal insufficiency. Am J Hematol. 2008;83(1):15-18.
25. Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Prevalence and risk factors of silent brain infarcts in the pop- ulation-based Rotterdam Scan Study. Stroke. 2002;33(1):21-25.
26. Kinney TR, Sleeper LA, Wang WC, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics. 1999;103(3):640-645.
27. Bernaudin F, Verlhac S, Arnaud C, et al. Chronic and acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemia. Blood. 2015;125(10):1653-1661.
28. van der Land V, Mutsaerts HJ, Engelen M, et al. Risk factor analysis of cerebral white matter hyperintensities in children with sickle cell disease. Br J Haematol. 2016;172 (2):274-284.
29. Leonardo FC, Brugnerotto AF, Domingos IF, et al. Reduced rate of sickle-related compli- cations in Brazilian patients carrying HbF- promoting alleles at the BCL11A and HMIP- 2 loci. Br J Haematol. 2016;173(3):456-460.
30. Reed GL, Houng AK, Singh S, Wang D. alpha2-Antiplasmin: new insights and opportunities for ischemic stroke. Semin Thromb Hemost. 2017;43(2):191-199.
31. Nezu T, Hosomi N, Aoki S, et al. Alpha2- macroglobulin as a promising biomarker for cerebral small vessel disease in acute ischemic stroke patients. J Neurol. 2013;260(10):2642-2649.
32. Mosesson MW. Fibrinogen gamma chain functions. J Thromb Haemost. 2003;1(2): 231-238.
33. Williams SR, Hsu FC, Keene KL, et al. Shared genetic susceptibility of vascular- related biomarkers with ischemic and recur- rent stroke. Neurology. 2016;86(4):351-359.
34. Faulcon LM, Fu Z, Dulloor P, et al. Thrombospondin-1 and L-selectin are asso- ciated with silent cerebral infarct in children with sickle cell anaemia. Br J Haematol. 2013;162(3):421-424.
35. Lance EI, Casella JF, Everett AD, Barron- Casella E. Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease. Proteomics Clin Appl. 2014;8(11-12):813-827.
36. Niculescu F, Rus H. The role of complement activation in atherosclerosis. Immunol Res. 2004;30(1):73-80.
37. Ray KK, Ginsberg HN, Davidson MH, et al. Reductions in atherogenic lipids and major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing alirocumab with control. Circulation. 2016;134(24): 1931-1943.
38. Kronenberg F, Stuhlinger M, Trenkwalder E, et al. Low apolipoprotein A-IV plasma con- centrations in men with coronary artery dis- ease. J Am Coll Cardiol. 2000;36(3):751-757.
39. Mack S, Coassin S, Vaucher J, Kronenberg F, Lamina C, Apo AIVGC. Evaluating the causal relation of ApoA-IV with disease- related traits - A bidirectional two-sample Mendelian randomization study. Sci Rep. 2017;7(1):8734.
40. Garcia-Berrocoso T, Penalba A, Boada C, et al. From brain to blood: new biomarkers for ischemic stroke prognosis. J Proteomics.
2013;94:138-148.
41. Silacci P, Mazzolai L, Gauci C, Stergiopulos
N, Yin HL, Hayoz D. Gelsolin superfamily proteins: key regulators of cellular func- tions. Cell Mol Life Sci. 2004;61(19-20): 2614-2623.
42. Llombart V, Garcia-Berrocoso T, Bustamante A, et al. Plasmatic retinol-binding protein 4 and glial fibrillary acidic protein as biomark- ers to differentiate ischemic stroke and intracerebral hemorrhage. J Neurochem. 2016;136(2):416-424.
43. Sasaki M, Otani T, Kawakami M, Ishikawa SE. Elevation of plasma retinol-binding pro- tein 4 and reduction of plasma adiponectin in subjects with cerebral infarction. Metabolism. 2010;59(4):527-532.
44. Famulla S, Lamers D, Hartwig S, et al. Pigment epithelium-derived factor (PEDF) is one of the most abundant proteins secreted by human adipocytes and induces insulin resistance and inflammatory signaling in muscle and fat cells. Int J Obes (Lond). 2011;35(6):762-772.
45. Ganesan V, Prengler M, Wade A, Kirkham FJ. Clinical and radiological recurrence after childhood arterial ischemic stroke. Circulation. 2006;114(20):2170-2177.
46. van der Land V, Peters M, Biemond BJ, Heijboer H, Harteveld CL, Fijnvandraat K. Markers of endothelial dysfunction differ between subphenotypes in children with sickle cell disease. Thromb Res. 2013;132(6):712-717.
47. Chen J, Hobbs WE, Le J, Lenting PJ, de Groot PG, Lopez JA. The rate of hemolysis in sick- le cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood. 2011;117(13):3680-3683.
48. Colombatti R, De Bon E, Bertomoro A, et al. Coagulation activation in children with sick- le cell disease is associated with cerebral small vessel vasculopathy. PLoS One. 2013;8(10):e78801.
49. Heeney MM, Hoppe CC, Abboud MR, et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med. 2016;374(7):625-635.
50. Hoppe C, Jacob E, Styles L, Kuypers F, Larkin S, Vichinsky E. Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. Br J Haematol. 2017;177(4):620-629.
1142
haematologica | 2018; 103(7)